 |
|
Continuing Treatment With Novel Antipsychotic Drugs Despite Leukopenia or Thrombocytopenia
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Novel antipsychotic medications are increasingly being used as first-line agents in treating schizophrenia as well as other psychotic disorders.1 Although olanzapine and quetiapine fumarate have not been reported to cause notable neutropenia, and blood monitoring is not required as is with clozapine, the following is a report of a case of persistent neutropenia in a patient treated with both agents.
Report of a Case
Ms L is a 50-year-old African American woman in a state prison for stabbing a man. She has a long history of schizophrenia (paranoid type). On admission to the Department of Corrections' mental health hospital, Ms L's white blood cell (WBC) count was 3000/µL. She had been receiving risperdal, 4 mg/d, prior to hospitalization, as well as previous typical antipsychotic medications in the past with little improvement. She was discharged from the hospital while receiving 200 mg of quetiapine per day.
She continued to have psychotic features while in a . . . [Full Text of this Article]
Comment
|
